Indianapolis’ newest publicly company, Point Biopharma Inc., is the latest player in a field expected to see explosive growth as doctors and researchers look for new ways to shrink tumors.
With the help of a $2.3 million grant, Purdue University animal science professor Shihuan Kuang’s research will continue in an effort to better understand the origin and function of these newly-discovered stem cells.
The use of COVID antibodies has fallen across the United States lately and, along with it, Lilly’s sales in that category.
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
Ossium Health wants to build a huge bank of bone marrow and stem cells from deceased organ donors to treat patient with blood cancers and to improve organ transplantations.
A startup that’s planning to launch a $60 million drug-manufacturing plant sees big growth in contract manufacturing.
The medical school said it is testing the use of tezampanel, an experimental drug for migraines developed by Indianapolis-based drugmaker Eli Lilly and Co., to treat opioid withdrawal syndrome and other addictions and mental illnesses.
Some of the vaccine trials in the United States are taking place at Indiana University School of Medicine in Indianapolis.
The grant will help fund an ongoing study to evaluate long-term health outcomes for cancer patients who receive life-saving chemotherapy treatments that often have difficult side effects.
Under the agreement, researchers will study patients who used Lilly autoimmune therapies that are under consideration for the treatment of other autoimmune diseases, including inflammatory bowel disease and psoriasis.
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
The International Council of Motorsport Sciences, established in Indianapolis in 1988, will relocate from Texas later this month after hiring veteran motorsports exec Tom Weisenbach as its new executive director.
Development Corp., is helping raise money for a women-focused cancer research initiative. The campaign, which will run through June, is in its second year.
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.
For companies that pursue technological advances and innovative solutions, bias can have an enduring impact, making it easy for the cycle to be perpetuated.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories.
The not-for-profit and its health research are a testament to the idea that all innovation is related—even when the connection appears tenuous at first glance.
The emerging health care field seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.
Health-data specialists at universities and research institutes in Indianapolis expect the virus to hit its peak between mid-April and early May, packing a punch that could cause about 800 new positive COVID-19 cases a day.
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
